National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Search for CCR Trials at NIH


Solid Tumor

A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma

NCI-11-C-0150, NCT01581541

Print this page 


Investigator(s):

Shivaani Kummar, M.D., F.A.C.P.
Principal Investigator
Phone: 301-435-0517
Fax: 301-496-0826
kummars@mail.nih.gov

Referral Contact(s):

Janelle Bingham, R.N.
Referral Coordinator
Phone: 301-435-2715
Fax: 301-451-5433
jbingham@mail.nih.gov

Lemual Clayborn
Referral Coordinator
Phone: 301-451-0992
Fax: 301-496-0826
claybornlr@mail.nih.gov

Ramya Parthasarathy, B.S.N., R.N., O.C.N.
Research Nurse
Phone: 301-594-4949
Fax: 301-480-7281
parthasarathyr@mail.nih.gov

 

Key Eligibility Criteria:

  • Histologically confirmed diagnosis of a solid tumor or low-grade non-Hodgkin lymphoma
  • Failed at least one line of prior therapy or have a disease for which no standard curative therapy exists
  • Measurable or evaluable disease
  • ECOG ≤ 2
  • Adequate organ and bone marrow function
  • Absolute neutrophil count ≥ 1,500/microL
  • Platelets ≥ 100,000/microL
  • AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal (ULN)
  • No uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements
  • Participants enrolling in the expansion phase must have disease amenable to biopsy and willing to undergo pre- and post-treatment biopsies
  • No therapy within 4 weeks of entering the study

Study Outline:

  • Screening physical examination; blood and tumor samples; and imaging studies to determine eligibility for the study
  • Patients will receive a fixed dose of PU-H71 intravenously (through a vein) once weekly, 2 weeks out of 3 (i.e., on Days 1 and 8) every 21 days (one cycle)
  • Cycles continue for as long as there is no progressive disease or unacceptable toxicity
  • Participants will be monitored with blood samples, physical examinations, and tumor imaging studies through the cycles of treatment

Additional Information:

  • This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
  • There is no charge for medical care received at NIH Clinical Center.
  • PDQ (Physicians Data Query) - provides additional details about this study for health care providers.


Reviewed: 9/12/12
Updated: 9/20/12

Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov